Allergan PLC has taken some flak from investors for a recent spate of smaller, earlier-stage deals, but the company’s executives say its “open science” strategy is paying off, most recently via the decision to exercise an option to buy Motus Therapeutics Inc. (formerly Rhythm Health Inc.) after completion of a successful Phase IIb clinical trial for the diabetic gastroparesis drug relamorelin.
Allergan didn’t reveal detailed results from the trial, but the data apparently were significant enough to justify the $200m option...
